A precision fragmenting instrument generating live tumor fragments with intact native tumor architecture and immune compartment High-speed sorter of tumor fragments into well pates, for downstream imaging and analysis An advanced three dimensional (3D) and label-free imaging platform using multiphoton microscopy to assess cell viability and metabolic activity in response to treatment An advanced three dimensional (3D) and label-free imaging platform using multiphoton microscopy to assess cell viability and metabolic activity in response to treatment
 
cybrid edge

A precision fragmenting instrument generating live tumor fragments with intact native tumor architecture and immune compartment.

cybrid edge
 
cybrid array

High-speed sorter of tumor fragments into well plates, for downstream imaging and analysis.

cybrid array
 
cybrid scope

An advanced three dimensional (3D) and label-free imaging platform using multiphoton microscopy to assess cell viability and metabolic activity in response to treatment.

cybrid scope
 
cybrid view

A dynamic visualization platform for analyzing 3D multiphoton images, multi-omic assays, secreted factors, and cell markers. All data and results delivered securely via the cloud.

cybrid view
 

Cybrid™ incorporates a comprehensive suite of assays to help understand the mechanisms of action of immunotherapeutic compounds indicating drug response.

 
Cell Markers

Measurement of cellular subsets and activation markers

Cytokines & Chemokines

Profiling of innate and adaptive immune response using secreted factors.

Transcriptomics

Detection of immune response at the mRNA level

Cybrid Platform Workflow

Tumor biopsy or resection

Tumor fragmentation

Fragment sorting & dispensing

Detect live tumor fragments & monitor drug response

Predict response & data visualization

 
 
 

Why use live tumor fragments (LTFs) over spheroids or organoids?

LTFs derived from tissue biopsies, retain the native tumor architecture, including all the immune cells which are required to predict response to immunotherapy.

Unlike spheroids or organoids, there is no expansion of cells or autologous infusion of immune cells, giving a faster turnaround time to test how effectively a drug works.

Additionally, LTFs allow us to look at immune cell infiltration which is predictive of response to therapy.

What is Elephas’ advantage of using multiphoton imaging over conventional techniques?

Conventional techniques such as confocal microscopy can be destructive and has limited penetration into the tissue sample.

Elephas’ multiphoton imaging is non-destructive, enables real-time monitoring of immune cells, and allows label-free imaging at significantly higher penetration depths to look at living tumors in 3D.

What is the benefit of combining multiphoton imaging and multiplexed assays to predict treatment response?

Multiplexed assays are routinely used to profile cell markers, cytokines, chemokines and mRNA expression to determine response to drugs.

By combining multiphoton imaging, we can analyze spatial and temporal information to visualize in the impact of drugs on cellular structures over time.

The combination of all these techniques also generates a vast amount of data that can be used to train AI algorithms to predict response to different therapies.